Mediphage Bioceuticals, a biotechnology company driving the next generation of genetic medicines, recently announced closing of its Seed financing round. A mix of early Mediphage supporters, including CCRM Enterprises Holdings Ltd, Riverine Ventures, and Bio Med Ventures, as well as new investors participated in the syndicate. The investment will drive the company’s internal therapeutic and manufacturing programs, while enabling Mediphage to continue supporting its growing number of external collaborations with pharmaceutical and biotechnology companies, CDMOs, and national research organizations.

Mediphage is an OBIO® member, an alumnus of our BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs and presented at the OBIO® Investment Summit.